Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
BioPact logo — A Molecular Rebar Design Company

BioPact

A Molecular Rebar Design Company

Founded 2014 United States Austin, United States 5 employees Biotechnology

General Information

Company Name BioPact
Founded Year 2014
Location United States Austin, United States +1
Employees 5
Industries Biotechnology
Social

Get notified when BioPact moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About BioPact

Biopact is a Molecular Rebar Design Company focusing on nanoscale biomaterials company developing the MGMR intracellular delivery vehicle. MGMR is a cellular-engineering tool for biomanufacturing and agricultural processes which value efficient delivery of RNAs, peptides, and genetic materials. MGMR is a highly-efficient intracellular delivery vehicle, consisting of a stabile dispersion of hollow, nanoscale tubules approximately 1/10,000th the width of a human hair. The high aspect-ratio, nanoscale profile of MGMR allows it to readily penetrate cells without compromising membrane integrity or inducing cytotoxicity. Its high surface-to-volume ratio and tunable surface chemistry allow it to readily transport both small and large-molecular payloads into the cytoplasm, including growth factors, oligonucleotides, proteins and gene-editing complexes. Biopact has evaluated the cytotoxicity profile of MGMR across multiple cell-lines and investigated safety and efficacy in murine biodistribution and clearance models. Our in vivo studies demonstrate that MGMR is biologically-inert, well-tolerated and rapidly cleared from non-targeted tissues. In a murine therapeutic model, MGMR loaded with doxorubicin (Dox) demonstrated a remarkable capability to rapidly concentrate drug in targeted tissues and extend half-life of its molecular cargo. Promising assessments of intracellular delivery performance in different eukaryotic cell-types suggest the potential for developing MGMR as a biomolecular delivery vehicle for various expression platforms and cell-factories of interest to agricultural and industrial applications, including mammalian cell-lines, yeasts, bacteria and plants. Robust cellular uptake observed with MGMR offers the potential to deliver molecular payloads to difficult-to-penetrate cell-types or those acutely sensitive to detergents and other conventional methods for transmembrane delivery.

No funding data available for BioPact yet.

Get notified when BioPact raises funding

FAQ About BioPact

A Molecular Rebar Design Company
BioPact was founded in 2014.
BioPact is headquartered in Austin, United States.
BioPact operates in the following industries: Biotechnology.
BioPact has approximately 5 employees.

We're actively collecting intelligence on BioPact.

Track BioPact to get notified

Don't just browse. Track.

Signal Tracker monitors BioPact and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy